1–3 of 3 results for Christine Kay
Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
Christine Kay, MD
Annual Meeting Talks
2023
Pooled Safety Analysis and Immunogenicity of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With AMD
2024
Suprachoroidally delivered gene therapy via non-viral DNA nanoparticles
On Demand Cases, Courses, and Papers
2019